Wolff Wiese Magana LLC Sells 935 Shares of Eli Lilly and Company $LLY

Wolff Wiese Magana LLC trimmed its stake in Eli Lilly and Company (NYSE:LLY) by 27.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,416 shares of the company’s stock after selling 935 shares during the period. Wolff Wiese Magana LLC’s holdings in Eli Lilly and Company were worth $1,843,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company during the 2nd quarter worth $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. grew its stake in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the second quarter valued at about $31,000. Finally, Bare Financial Services Inc raised its position in shares of Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several research reports. The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Bank of America cut their price objective on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a report on Monday, December 15th. Finally, JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $1,174.70.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan coverage highlights continued GLP‑1 sales strength and pipeline-driven momentum entering 2026, reinforcing expectations for revenue growth from obesity and next‑generation incretin candidates. JPM26: Eli Lilly enters 2026 with strong momentum given pipeline innovation
• Positive Sentiment: JPMorgan also highlights commercial and governmental access efforts for Lilly’s obesity drugs — implying management focus on scaling reimbursement and market penetration, which supports longer‑term sales trajectory. JPM26: Eli Lilly’s obesity drugs target commercial and governmental access
• Positive Sentiment: Analysts continue to back LLY: Jefferies reaffirmed a Buy with a $1,300 target and BMO kept a Buy — signals that sell‑side expectations remain bullish despite near‑term noise. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: CEO David Ricks reiterated ambition and portfolio outlook (including obesity launches) in a recent interview, which supports confidence in execution and the company’s sizable market opportunity. Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook
• Neutral Sentiment: Lilly’s AI collaboration mentions (e.g., with NVIDIA) position the company on the technological edge of drug discovery — positive structurally but not an immediate revenue driver. JPM: NVIDIA Launches AI Collaborations with Eli Lilly, Thermo Fisher
• Negative Sentiment: FDA reportedly delayed its decision on Lilly’s oral obesity candidate orforglipron (a priority‑voucher recipient), creating uncertainty about near‑term market timing and catalyzing a negative trader reaction. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report
• Negative Sentiment: A compounding pharmacy has filed suit alleging coordinated conduct by Lilly and Novo Nordisk around GLP‑1 dominance; legal/legal‑risk headlines add regulatory and reputational uncertainty for the GLP‑1 franchise. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,032.51 on Friday. The stock has a market capitalization of $976.11 billion, a price-to-earnings ratio of 50.51, a PEG ratio of 0.78 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm’s 50 day simple moving average is $1,049.04 and its 200-day simple moving average is $868.38. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.